Free Trial
→ The End of Elon Musk…? (From Brownstone Research) (Ad) Free TRVI Stock Alerts

Trevi Therapeutics (TRVI) Financials

Trevi Therapeutics logo
$6.55 +0.14 (+2.18%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$6.78 +0.23 (+3.51%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Trevi Therapeutics

Annual Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -26 -27 -33 -34 -29 -29 -48
Consolidated Net Income / (Loss)		 -21 -26 -33 -34 -29 -29 -48
Net Income / (Loss) Continuing Operations		 -21 -26 -33 -34 -29 -29 -48
Total Pre-Tax Income 		-21 -26 -33 -34 -29 -29 -48
Total Operating Income		 -18 -27 -32 -32 -30 -34 -52
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 18 27 32 32 30 34 52
Selling, General & Admin Expense		 4.34 7.31 10 9.49 10 10 12
Research & Development Expense		 14 19 22 23 20 24 39
Total Other Income / (Expense), net		 -2.26 0.58 -0.29 -1.49 0.72 4.83 3.58
Interest Expense		 0.17 0.00 0.46 1.20 1.16 0.39 0.00
Interest & Investment Income		 0.16 0.79 0.18 0.01 1.74 4.75 3.60
Other Income / (Expense), net		 -2.24 -0.22 -0.01 -0.29 0.14 0.47 -0.02
Income Tax Expense		 -0.12 -0.02 -0.02 -0.02 -0.04 -0.03 -0.03
Basic Earnings per Share		 ($58.44) ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47)
Weighted Average Basic Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 64.54M 99.03M 101.97M
Diluted Earnings per Share		 ($58.44) ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47)
Weighted Average Diluted Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 64.54M 99.03M 101.97M
Weighted Average Basic & Diluted Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 60.05M 68.96M 96.68M

Quarterly Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.27 -5.51 -6.40 -7.15 -7.67 -7.85 -11 -12 -13 -12 -10
Consolidated Net Income / (Loss)		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11 -10
Net Income / (Loss) Continuing Operations		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11 -10
Total Pre-Tax Income 		-8.27 -5.53 -6.41 -7.18 -7.71 -7.80 -11 -12 -13 -11 -10
Total Operating Income		 -8.41 -6.66 -7.56 -8.38 -9.05 -8.93 -12 -13 -14 -12 -11
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.41 6.66 7.56 8.38 9.05 8.93 12 13 14 12 11
Selling, General & Admin Expense		 2.64 2.34 2.56 2.54 2.72 2.42 3.10 3.27 2.86 2.91 3.66
Research & Development Expense		 5.77 4.32 5.00 5.84 6.32 6.52 8.80 10 11 9.33 7.81
Total Other Income / (Expense), net		 0.13 1.13 1.16 1.21 1.33 1.13 1.00 0.93 0.81 0.84 1.12
Interest Expense		 0.29 0.27 0.23 0.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest & Investment Income		 0.42 1.12 1.22 1.21 1.18 1.14 1.00 0.94 0.83 0.84 1.13
Other Income / (Expense), net		 0.00 0.29 0.17 0.15 0.15 -0.00 -0.00 -0.01 -0.01 0.00 -0.01
Income Tax Expense		 -0.01 -0.02 -0.01 -0.03 -0.01 0.02 -0.01 -0.01 -0.03 0.02 -0.01
Basic Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09)
Weighted Average Basic Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M
Diluted Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09)
Weighted Average Diluted Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M
Weighted Average Basic & Diluted Shares Outstanding		 59.92M 60.05M 60.07M 63.85M 63.86M 68.96M 70.44M 72.59M 76.87M 96.68M 101.74M

Annual Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -15 50 -12 -8.17 -24 20 1.70
Net Cash From Operating Activities		 -18 -23 -29 -29 -28 -32 -38
Net Cash From Continuing Operating Activities		 -18 -23 -29 -29 -28 -32 -38
Net Income / (Loss) Continuing Operations		 -21 -26 -33 -34 -29 -29 -48
Consolidated Net Income / (Loss)		 -21 -26 -33 -34 -29 -29 -48
Depreciation Expense		 0.02 0.04 0.05 0.05 0.04 0.12 0.15
Amortization Expense		 0.06 0.00 0.23 0.60 -0.31 -1.95 -1.37
Non-Cash Adjustments To Reconcile Net Income		 2.77 0.97 2.43 2.84 2.47 3.02 4.05
Changes in Operating Assets and Liabilities, net		 -0.64 1.95 1.06 1.51 -1.23 -3.85 6.83
Net Cash From Investing Activities		 -0.16 -0.01 -0.03 0.00 -107 59 -22
Net Cash From Continuing Investing Activities		 -0.16 -0.01 -0.03 0.00 -107 59 -22
Purchase of Property, Plant & Equipment		 -0.16 -0.01 -0.03 0.00 -0.16 -0.14 -0.04
Purchase of Investments		 - - - 0.00 -126 -9.93 -98
Sale and/or Maturity of Investments		 - - - 0.00 19 69 77
Net Cash From Financing Activities		 3.63 73 17 21 111 -7.91 61
Net Cash From Continuing Financing Activities		 3.63 73 17 21 111 -7.91 61
Repayment of Debt		 -4.81 0.00 -0.08 -0.07 -5.85 -9.41 0.00
Repurchase of Common Equity		 -1.53 -1.21 -0.38 -0.38 -0.23 -0.26 0.00
Issuance of Common Equity		 0.00 65 0.01 14 105 0.07 0.07
Other Financing Activities, net		 -0.52 -0.64 3.17 7.51 12 1.69 61
Cash Interest Paid		 0.15 0.00 0.18 0.60 0.59 0.33 0.00

Quarterly Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 42 -54 -0.94 2.10 12 6.43 -19 -0.85 3.09 18 -15
Net Cash From Operating Activities		 -8.58 -6.33 -8.20 -9.88 -7.28 -6.36 -10 -8.68 -9.56 -9.55 -13
Net Cash From Continuing Operating Activities		 -8.58 -6.33 -8.20 -9.88 -7.28 -6.36 -10 -8.68 -9.56 -9.55 -14
Net Income / (Loss) Continuing Operations		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11 -10
Consolidated Net Income / (Loss)		 -8.27 -5.51 -6.40 -7.15 -7.70 -7.82 -11 -12 -13 -11 -10
Depreciation Expense		 0.01 0.02 0.02 0.03 0.04 0.04 0.04 0.04 0.04 0.04 0.04
Amortization Expense		 -0.07 -0.46 -0.59 -0.39 -0.61 -0.35 -0.38 -0.34 -0.35 -0.30 -0.40
Non-Cash Adjustments To Reconcile Net Income		 0.60 0.40 0.59 0.61 0.79 1.04 0.84 1.24 0.85 1.12 1.21
Changes in Operating Assets and Liabilities, net		 -0.85 -0.78 -1.81 -2.98 0.21 0.74 -0.06 2.73 3.15 1.01 -4.10
Net Cash From Investing Activities		 -4.85 -48 8.96 20 18 13 -8.09 2.77 7.67 -24 -9.95
Net Cash From Continuing Investing Activities		 -4.85 -48 8.96 20 18 13 -8.09 2.77 7.67 -24 -9.95
Purchase of Investments		 -6.81 -65 -8.98 - - -0.95 -30 -9.96 -13 -45 -28
Sale and/or Maturity of Investments		 2.00 17 18 20 18 14 22 13 21 21 18
Net Cash From Financing Activities		 55 0.65 -1.70 -7.66 1.51 -0.05 -0.03 5.07 4.98 51 8.71
Net Cash From Continuing Financing Activities		 55 0.65 -1.70 -7.66 1.51 -0.05 -0.03 5.07 4.98 51 8.71
Repurchase of Common Equity		 -0.16 -0.03 -0.02 -0.01 -0.17 -0.06 0.00 - - - -0.22
Other Financing Activities, net		 6.03 - 0.06 -0.02 1.68 -0.03 -0.03 5.03 4.98 51 8.93

Annual Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 11 60 47 38 123 89 111
Total Current Assets		 8.82 60 46 38 123 88 109
Cash & Equivalents		 7.20 57 45 37 13 32 34
Short-Term Investments		 - - - 0.00 108 51 74
Prepaid Expenses		 1.44 1.68 1.00 0.89 0.80 3.62 0.94
Other Current Assets		 0.18 0.56 0.27 0.24 1.31 0.96 0.87
Plant, Property, & Equipment, net		 0.15 0.12 0.10 0.05 0.17 0.22 0.16
Total Noncurrent Assets		 1.55 0.33 0.76 0.47 0.23 1.64 1.32
Noncurrent Note & Lease Receivables		 - - - - 0.00 0.21 0.16
Other Noncurrent Operating Assets		 1.55 0.33 0.76 0.47 0.23 1.43 1.16
Total Liabilities & Shareholders' Equity		 11 60 47 38 123 89 111
Total Liabilities		 4.28 5.46 20 21 16 6.86 11
Total Current Liabilities		 2.68 5.20 5.56 13 13 5.82 11
Accounts Payable		 0.60 1.60 2.02 2.85 2.86 1.81 3.41
Accrued Expenses		 2.07 3.50 3.43 3.81 3.52 3.71 6.81
Other Current Liabilities		 0.00 0.10 0.11 0.23 0.03 0.31 0.29
Total Noncurrent Liabilities		 1.60 0.26 14 8.68 2.16 1.03 0.75
Long-Term Debt		 - 0.00 14 8.65 2.15 0.00 0.00
Other Noncurrent Operating Liabilities		 1.56 0.00 0.20 0.00 0.00 0.03 0.75
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -109 55 27 17 107 83 100
Total Preferred & Common Equity		 -109 55 27 17 107 83 100
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -109 55 27 17 107 83 100
Common Stock		 0.00 169 174 198 318 322 387
Retained Earnings		 -109 -114 -147 -181 -210 -239 -287
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 -0.12 -0.03 0.06

Quarterly Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 81 128 116 101 96 79 74 69 107
Total Current Assets		 80 127 114 99 94 77 72 67 106
Cash & Equivalents		 25 67 12 14 26 14 13 16 19
Short-Term Investments		 53 59 100 80 63 59 57 49 84
Prepaid Expenses		 1.65 1.29 1.33 2.98 4.04 3.23 1.80 1.18 1.53
Other Current Assets		 0.38 0.42 1.61 2.08 1.05 0.72 0.83 0.67 0.83
Plant, Property, & Equipment, net		 0.03 0.07 0.25 0.23 0.24 0.20 0.20 0.17 0.28
Total Noncurrent Assets		 1.50 0.92 1.76 1.54 1.71 1.59 1.48 1.40 1.11
Noncurrent Note & Lease Receivables		 - - 0.24 0.23 0.22 0.19 0.18 0.17 0.00
Other Noncurrent Operating Assets		 0.50 0.92 1.52 1.31 1.49 1.40 1.30 1.23 1.11
Total Liabilities & Shareholders' Equity		 81 128 116 101 96 79 74 69 107
Total Liabilities		 21 18 14 5.90 6.29 6.23 7.64 9.94 7.55
Total Current Liabilities		 15 15 13 4.71 5.17 5.28 6.75 9.12 6.87
Accounts Payable		 3.94 2.33 1.98 1.35 1.26 2.11 1.51 1.61 1.42
Accrued Expenses		 4.40 5.25 3.47 3.08 3.63 2.84 4.93 7.21 5.17
Other Current Liabilities		 0.09 0.06 0.26 0.28 0.29 0.32 0.31 0.30 0.28
Total Noncurrent Liabilities		 5.47 3.82 1.27 1.19 1.11 0.95 0.88 0.82 0.68
Long-Term Debt		 5.43 3.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.04 0.02 0.12 0.09 0.06 0.00 0.00 0.00 0.68
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 61 110 102 95 90 72 66 59 99
Total Preferred & Common Equity		 61 110 102 95 90 72 66 59 99
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 61 110 102 95 90 72 66 59 99
Common Stock		 257 315 318 319 321 322 329 334 397
Retained Earnings		 -196 -205 -216 -224 -231 -250 -262 -276 -297
Accumulated Other Comprehensive Income / (Loss)		 -0.14 -0.26 -0.09 -0.25 -0.22 -0.07 -0.08 0.14 0.07

Annual Metrics And Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -30.40% -20.14% 0.32% 6.50% -17.47% -49.56%
EBIT Growth		 0.00% -30.07% -20.99% -0.83% 9.17% -12.39% -54.06%
NOPAT Growth		 0.00% -44.75% -21.93% 0.04% 7.91% -13.43% -51.89%
Net Income Growth		 0.00% -26.79% -25.75% -3.61% 14.11% 0.30% -64.84%
EPS Growth		 0.00% 96.10% 20.61% 17.68% 69.80% 35.56% -62.07%
Operating Cash Flow Growth		 0.00% -26.27% -25.58% 0.19% 2.66% -12.55% -20.64%
Free Cash Flow Firm Growth		 0.00% 0.00% -26.89% 2.42% -5.57% -26.65% -0.13%
Invested Capital Growth		 0.00% -176.54% -44.21% -44.88% 25.70% 114.80% -1,353.21%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -2.65% -7.59% 2.96% 3.96% -7.43% -6.56%
EBIT Q/Q Growth		 0.00% -2.63% -8.10% 2.91% 5.86% -8.31% -6.85%
NOPAT Q/Q Growth		 0.00% -3.24% -8.07% 2.75% 5.13% -7.19% -6.86%
Net Income Q/Q Growth		 0.00% -2.18% -10.03% 2.87% 9.37% -8.66% -8.11%
EPS Q/Q Growth		 0.00% 92.80% -116.00% 15.82% 38.36% -81.25% -6.82%
Operating Cash Flow Q/Q Growth		 0.00% -6.80% -10.36% 8.52% -0.36% -0.09% -9.10%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -7.90% 9.35% -7.25% 2.17% -7.65%
Invested Capital Q/Q Growth		 0.00% 0.48% -2.96% -45.32% 20.45% -67.82% -26.68%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.40% 99.93% 99.95% 99.94% 99.88% 99.89% 99.94%
Interest Burden Percent		 100.09% 97.05% 100.86% 103.64% 98.06% 86.98% 93.02%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -328.83% -85.70% -80.07% -153.03% -46.82% -30.59% -52.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -4,891.01% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 5,762.55% 77.46% -80.07% -153.03% -46.82% -30.59% -52.59%
Return on Equity Simple (ROE_SIMPLE)		 18.76% -47.76% -120.07% -198.77% -27.13% -35.21% -48.08%
Net Operating Profit after Tax (NOPAT)		 -13 -19 -23 -23 -21 -24 -36
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -107.03% -23.04% -22.77% -42.11% -12.29% -5.50% -12.54%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -28.42% -35.93%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -21 -27 -32 -33 -30 -33 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -27 -32 -32 -30 -35 -53
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 1.23 1.63 1.18 1.08 1.04 3.18
Price to Tangible Book Value (P/TBV)		 0.00 1.23 1.63 1.18 1.08 1.04 3.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 6.24 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.01 0.00 0.52 0.85 0.09 0.01 0.01
Long-Term Debt to Equity		 0.01 0.00 0.52 0.51 0.02 0.01 0.01
Financial Leverage		 -1.15 -1.06 -1.07 -1.20 -1.07 -1.02 -1.04
Leverage Ratio		 1.68 1.16 1.31 1.93 1.30 1.12 1.10
Compound Leverage Factor		 1.69 1.13 1.32 2.00 1.27 0.97 1.02
Debt to Total Capital		 0.73% 0.47% 34.07% 45.94% 7.85% 1.20% 0.74%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 18.47% 6.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.73% 0.47% 34.07% 27.47% 1.85% 1.20% 0.74%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1,838.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -1,739.66% 99.53% 65.93% 54.06% 92.15% 98.80% 99.26%
Debt to EBITDA		 0.00 -0.01 -0.44 -0.45 -0.30 -0.03 -0.01
Net Debt to EBITDA		 0.35 2.13 0.96 0.69 3.71 2.32 2.03
Long-Term Debt to EBITDA		 0.00 -0.01 -0.44 -0.27 -0.07 -0.03 -0.01
Debt to NOPAT		 0.00 -0.01 -0.62 -0.64 -0.44 -0.04 -0.02
Net Debt to NOPAT		 0.56 3.06 1.36 0.98 5.32 3.45 2.96
Long-Term Debt to NOPAT		 0.00 -0.01 -0.62 -0.38 -0.10 -0.04 -0.02
Altman Z-Score		 -12.62 4.30 -4.26 -8.04 2.34 3.61 12.79
Noncontrolling Interest Sharing Ratio		 1,852.46% 190.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 3.30 11.45 8.33 2.98 9.15 15.03 10.41
Quick Ratio		 2.69 11.02 8.10 2.89 8.99 14.25 10.24
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -17 -22 -21 -22 -28 -28
Operating Cash Flow to CapEx		 -11,575.32% -256,588.89% -90,625.00% 0.00% -17,720.13% -23,145.99% -109,302.86%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -47.44 -17.56 -19.16 -72.18 -7,064.70
Operating Cash Flow to Interest Expense		 -105.11 0.00 -63.60 -24.08 -24.23 -81.10 -9,564.00
Operating Cash Flow Less CapEx to Interest Expense		 -106.02 0.00 -63.67 -24.08 -24.36 -81.45 -9,572.75
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -0.91 -2.51 -3.62 -5.25 -3.90 0.58 -7.23
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -1.60 -1.11 -1.63 1.35 4.48 -7.81
Enterprise Value (EV)		 164 9.82 14 -2.10 4.29 3.60 210
Market Capitalization		 55 67 44 20 116 86 317
Book Value per Share		 ($250.21) $3.06 $1.48 $0.66 $1.79 $1.29 $1.30
Tangible Book Value per Share		 ($250.21) $3.06 $1.48 $0.66 $1.79 $1.29 $1.30
Total Capital		 6.29 55 41 32 117 84 100
Total Debt		 0.05 0.26 14 15 9.15 1.00 0.75
Total Long-Term Debt		 0.05 0.26 14 8.68 2.15 1.00 0.75
Net Debt		 -7.16 -57 -31 -22 -111 -82 -107
Capital Expenditures (CapEx)		 0.16 0.01 0.03 0.00 0.16 0.14 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.05 -2.96 -4.29 -5.76 -4.29 -1.25 -8.70
Debt-free Net Working Capital (DFNWC)		 6.15 54 41 31 116 82 99
Net Working Capital (NWC)		 6.15 54 41 25 109 82 99
Net Nonoperating Expense (NNE)		 7.66 7.40 10 11 8.22 5.32 12
Net Nonoperating Obligations (NNO)		 -7.16 -57 -31 -22 -111 -82 -107
Total Depreciation and Amortization (D&A)		 0.08 0.04 0.27 0.65 -0.27 -1.82 -1.22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 17.83M 19.91M 30.81M 64.54M 99.03M 101.97M
Adjusted Diluted Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 17.83M 19.91M 30.81M 64.54M 99.03M 101.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 11.74M 18.06M 22.84M 60.05M 68.96M 96.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -19 -23 -23 -21 -24 -36
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -118.68 0.00 -71.27 -27.26 -25.59 -85.56 -12,884.75
NOPAT to Interest Expense		 -74.06 0.00 -49.87 -18.91 -18.00 -60.73 -9,016.70
EBIT Less CapEx to Interest Expense		 -119.59 0.00 -71.34 -27.26 -25.73 -85.91 -12,893.50
NOPAT Less CapEx to Interest Expense		 -74.96 0.00 -49.94 -18.91 -18.14 -61.08 -9,025.45
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -7.47% -4.66% -1.15% -1.13% -0.78% -0.89% 0.00%

Quarterly Metrics And Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -24.78% 15.38% -15.98% -9.01% -11.78% -35.80% -53.76% -58.29% -52.25% -35.10% 3.42%
EBIT Growth		 -20.90% 22.53% -5.15% -3.43% -5.78% -40.33% -60.95% -61.55% -58.56% -36.97% 3.62%
NOPAT Growth		 -20.99% 19.53% -7.66% -7.19% -7.61% -34.19% -57.42% -58.54% -55.74% -37.04% 3.66%
Net Income Growth		 -13.94% 35.39% 12.66% 11.26% 6.87% -42.07% -70.32% -72.88% -72.02% -45.95% 5.16%
EPS Growth		 64.71% 121.74% 75.00% 50.00% 33.33% -260.00% -83.33% -71.43% -62.50% -37.50% 18.18%
Operating Cash Flow Growth		 -18.44% -1.64% -15.58% -59.89% 15.12% -0.44% -27.69% 12.07% -31.28% -50.18% -28.76%
Free Cash Flow Firm Growth		 3.70% -44.21% -118.81% -244.16% -183.54% -78.57% -7.80% 64.89% 81.88% 92.90% 61.15%
Invested Capital Growth		 -35.73% 25.70% 80.50% 134.20% 136.59% 114.80% 151.67% -220.58% -418.35% -1,353.21% -920.73%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -7.53% 19.56% -16.97% -7.76% -10.26% 2.28% -32.44% -10.93% -6.06% 13.29% 5.32%
EBIT Q/Q Growth		 -5.64% 24.24% -16.17% -11.23% -8.04% -0.51% -33.25% -11.65% -6.05% 13.18% 6.24%
NOPAT Q/Q Growth		 -7.48% 20.80% -13.61% -10.83% -7.91% 1.24% -33.28% -11.62% -6.01% 13.10% 6.31%
Net Income Q/Q Growth		 -2.66% 33.40% -16.28% -11.62% -7.74% -1.60% -39.39% -13.30% -7.21% 13.80% 9.42%
EPS Q/Q Growth		 14.29% 141.67% -220.00% -16.67% -14.29% 0.00% -37.50% -9.09% -8.33% 15.38% 18.18%
Operating Cash Flow Q/Q Growth		 -38.86% 26.18% -29.47% -20.47% 26.29% 12.64% -64.60% 17.04% -10.05% 0.06% -41.12%
Free Cash Flow Firm Q/Q Growth		 -14.58% -30.79% -49.67% -53.44% 5.60% 17.63% 9.65% 50.02% 51.29% 67.74% -394.62%
Invested Capital Q/Q Growth		 17.08% 20.45% 77.01% 325.56% -11.28% -67.82% -19.76% -626.35% -134.22% -26.68% 47.45%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.92% 99.64% 99.89% 99.58% 99.83% 100.23% 99.93% 99.94% 99.77% 100.15% 99.89%
Interest Burden Percent		 98.43% 86.76% 86.62% 87.19% 86.73% 87.32% 91.63% 92.97% 94.15% 93.12% 90.20%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -53.04% -46.82% -50.31% -35.11% -26.81% -30.59% -38.57% -48.09% -59.65% -52.59% -55.12%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,466.35% -1,608.81% -4,891.01% -6,078.88% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -53.04% -46.82% -50.31% -35.11% -26.81% -30.59% -38.57% -48.09% -59.65% -52.59% -55.12%
Return on Equity Simple (ROE_SIMPLE)		 -29.27% 0.00% -27.74% -28.73% -29.85% 0.00% -46.40% -58.59% -75.15% 0.00% -47.61%
Net Operating Profit after Tax (NOPAT)		 -5.88 -4.66 -5.29 -5.87 -6.33 -6.25 -8.33 -9.30 -9.86 -8.57 -8.03
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.67% -1.26% -1.88% -1.60% -1.35% -1.62% -2.94% -3.77% -4.43% -3.01% -2.64%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -7.48% - - - -8.54% -8.07%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.41 -6.37 -7.40 -8.23 -8.89 -8.94 -12 -13 -14 -12 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.47 -6.81 -7.97 -8.59 -9.47 -9.25 -12 -14 -14 -12 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.60 1.08 1.09 1.51 1.55 1.04 3.29 3.17 4.11 3.18 6.11
Price to Tangible Book Value (P/TBV)		 0.60 1.08 1.09 1.51 1.55 1.04 3.29 3.17 4.11 3.18 6.11
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 24.99 28.65 6.24 358.62 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.10 0.09 0.08 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Long-Term Debt to Equity		 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Financial Leverage		 -1.07 -1.07 -1.05 -1.03 -1.02 -1.02 -1.00 -1.00 -1.03 -1.04 -1.02
Leverage Ratio		 1.32 1.30 1.31 1.17 1.12 1.12 1.12 1.08 1.11 1.10 1.08
Compound Leverage Factor		 1.30 1.13 1.13 1.02 0.97 0.98 1.03 1.01 1.04 1.02 0.97
Debt to Total Capital		 8.95% 7.85% 7.82% 1.14% 1.16% 1.20% 1.30% 1.32% 1.36% 0.74% 0.00%
Short-Term Debt to Total Capital		 5.80% 6.00% 6.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 3.15% 1.85% 1.04% 1.14% 1.16% 1.20% 1.30% 1.32% 1.36% 0.74% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.05% 92.15% 92.18% 98.86% 98.84% 98.80% 98.71% 98.68% 98.64% 99.26% 100.00%
Debt to EBITDA		 -0.35 -0.30 -0.28 -0.03 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01 0.00
Net Debt to EBITDA		 3.67 3.71 3.30 2.92 2.67 2.32 1.82 1.54 1.31 2.03 0.00
Long-Term Debt to EBITDA		 -0.12 -0.07 -0.04 -0.03 -0.03 -0.03 -0.02 -0.02 -0.02 -0.01 0.00
Debt to NOPAT		 -0.49 -0.44 -0.40 -0.05 -0.05 -0.04 -0.04 -0.03 -0.02 -0.02 0.00
Net Debt to NOPAT		 5.20 5.32 4.82 4.29 3.96 3.45 2.68 2.27 1.92 2.96 0.00
Long-Term Debt to NOPAT		 -0.17 -0.10 -0.05 -0.05 -0.05 -0.04 -0.04 -0.03 -0.02 -0.02 0.00
Altman Z-Score		 0.75 2.96 2.83 12.34 10.71 4.51 19.07 11.98 9.38 13.96 45.21
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.70 9.15 8.65 21.06 18.16 15.03 14.55 10.68 7.38 10.41 15.38
Quick Ratio		 8.58 8.99 8.43 19.99 17.18 14.25 13.80 10.29 7.18 10.24 15.04
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.59 -6.01 -8.99 -14 -13 -11 -9.69 -4.84 -2.36 -0.76 -3.77
Operating Cash Flow to CapEx		 -19,944.19% -5,457.76% -14,380.70% -24,687.50% -40,438.89% -28,904.55% 0.00% -31,010.71% 0.00% -136,428.57% 0.00%
Free Cash Flow to Firm to Interest Expense		 -15.73 -21.93 -38.93 -90.18 -4,341.50 -2,682.03 -9,693.20 -4,844.30 -2,359.90 -761.40 0.00
Operating Cash Flow to Interest Expense		 -29.37 -23.11 -35.48 -64.54 -2,426.33 -1,589.75 -10,467.00 -8,683.00 -9,556.00 -9,550.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -29.52 -23.53 -35.73 -64.80 -2,432.33 -1,595.25 -10,467.00 -8,711.00 -9,556.00 -9,557.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.90 -3.90 -0.90 2.02 1.79 0.58 0.46 -2.44 -5.71 -7.23 -3.80
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.29 1.35 3.70 7.93 6.69 4.48 1.36 -4.46 -7.50 -7.81 -4.26
Enterprise Value (EV)		 -49 4.29 8.46 51 51 3.60 166 141 178 210 505
Market Capitalization		 66 116 111 144 139 86 238 210 242 317 608
Book Value per Share		 $2.57 $1.79 $1.69 $1.58 $1.40 $1.29 $1.05 $0.94 $0.81 $1.30 $1.03
Tangible Book Value per Share		 $2.57 $1.79 $1.69 $1.58 $1.40 $1.29 $1.05 $0.94 $0.81 $1.30 $1.03
Total Capital		 121 117 110 96 91 84 73 67 60 100 99
Total Debt		 11 9.15 8.63 1.10 1.05 1.00 0.95 0.88 0.82 0.75 0.00
Total Long-Term Debt		 3.80 2.15 1.15 1.10 1.05 1.00 0.95 0.88 0.82 0.75 0.00
Net Debt		 -115 -111 -103 -93 -88 -82 -72 -69 -65 -107 -103
Capital Expenditures (CapEx)		 0.04 0.12 0.06 0.04 0.02 0.02 0.00 0.03 0.00 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.93 -4.29 -2.78 0.35 -0.09 -1.25 -1.33 -4.12 -7.28 -8.70 -4.50
Debt-free Net Working Capital (DFNWC)		 120 116 108 95 89 82 71 65 58 99 99
Net Working Capital (NWC)		 113 109 101 95 89 82 71 65 58 99 99
Net Nonoperating Expense (NNE)		 2.38 0.85 1.11 1.28 1.37 1.57 2.57 3.05 3.38 2.85 2.31
Net Nonoperating Obligations (NNO)		 -115 -111 -103 -93 -88 -82 -72 -69 -65 -107 -103
Total Depreciation and Amortization (D&A)		 -0.07 -0.45 -0.57 -0.36 -0.58 -0.32 -0.35 -0.30 -0.32 -0.26 -0.36
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M
Adjusted Diluted Earnings per Share		 ($0.12) $0.05 ($0.06) ($0.07) ($0.08) ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 68.90M 64.54M 98.61M 98.70M 99.33M 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.92M 60.05M 60.07M 63.85M 63.86M 68.96M 70.44M 72.59M 76.87M 96.68M 101.74M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.88 -4.66 -5.29 -5.87 -6.33 -6.25 -8.33 -9.30 -9.86 -8.57 -8.03
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -28.78 -23.24 -32.03 -53.78 -2,963.67 -2,234.00 -11,907.00 -13,294.00 -14,098.00 -12,240.00 0.00
NOPAT to Interest Expense		 -20.15 -17.01 -22.92 -38.35 -2,110.50 -1,563.28 -8,334.20 -9,302.30 -9,860.90 -8,569.40 0.00
EBIT Less CapEx to Interest Expense		 -28.93 -23.66 -32.27 -54.05 -2,969.67 -2,239.50 -11,907.00 -13,322.00 -14,098.00 -12,247.00 0.00
NOPAT Less CapEx to Interest Expense		 -20.30 -17.43 -23.16 -38.61 -2,116.50 -1,568.78 -8,334.20 -9,330.30 -9,860.90 -8,576.40 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.49% -0.78% -0.70% -0.81% -0.86% -0.89% -0.72% -0.59% -0.13% 0.00% -0.47%

Key Financial Trends

Trevi Therapeutics remains a pre-commercial biotech with no revenue to date but carries a strong cash position. Quarterly losses continue, though certain operating metrics have improved sequentially.

  • Strong liquidity: $19.4M cash & $83.9M short-term investments, for a current ratio of ~15x, underpin runway.
  • High Altman Z-Score: 45.2 in Q1’25 signaling very low risk of financial distress.
  • Improving EPS trend: Adjusted EPS narrowed to -$0.09 in Q1’25 vs. -$0.11 in Q4’24 and -$0.13 in Q3’24.
  • Controlled R&D spend: R&D expense down to $7.8M in Q1’25 from $11.2M in Q3’24 and $9.3M in Q4’24, helping to moderate cash burn.
  • No revenue: Still in the R&D stage with no commercial sales, reliant on financing.
  • Valuation metric: Price-to-book of ~6.1x reflects value of pipeline and cash buffer.
  • Continued losses: Q1’25 operating loss of $11.5M and net cash used in operations of $13.6M remain substantial.
  • Negative free cash flow: FCFF was -$3.8M in Q1’25 and has been negative most quarters, draining cash reserves.
  • Slowing financing: Net financing inflows fell to $8.7M in Q1’25 from $51.5M in Q4’24, reducing runway extension.
  • Dilution risk: Share count rose to 117.6M in Q1’25 from 101.7M in Q4’24, pressuring EPS further.
  • High operating expenses: Combined R&D and SG&A of $11.5M in Q1’25 continue to drive heavy cash outflows.
07/14/25 06:45 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Trevi Therapeutics' Financials

When does Trevi Therapeutics' financial year end?

According to the most recent income statement we have on file, Trevi Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Trevi Therapeutics' net income changed over the last 6 years?

Trevi Therapeutics' net income appears to be on an upward trend, with a most recent value of -$47.91 million in 2024, rising from -$20.55 million in 2018. The previous period was -$29.07 million in 2023. Check out Trevi Therapeutics' forecast to explore projected trends and price targets.

What is Trevi Therapeutics' operating income?
Trevi Therapeutics' total operating income in 2024 was -$51.52 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $51.52 million
How has Trevi Therapeutics' revenue changed over the last 6 years?

Over the last 6 years, Trevi Therapeutics' total revenue changed from $0.00 in 2018 to $0.00 in 2024, a change of 0.0%.

How much debt does Trevi Therapeutics have?

Trevi Therapeutics' total liabilities were at $11.26 million at the end of 2024, a 64.2% increase from 2023, and a 163.1% increase since 2018.

How much cash does Trevi Therapeutics have?

In the past 6 years, Trevi Therapeutics' cash and equivalents has ranged from $7.20 million in 2018 to $57.31 million in 2019, and is currently $34.10 million as of their latest financial filing in 2024.

How has Trevi Therapeutics' book value per share changed over the last 6 years?

Over the last 6 years, Trevi Therapeutics' book value per share changed from -250.21 in 2018 to 1.30 in 2024, a change of -100.5%.


Related Companies

This page (NASDAQ:TRVI) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
This Social Security Shift Could Boost Benefits by 400%
If you currently collect Social Security—or plan to in the future—this may be one of the most important update...
InvestorPlace | Sponsored
Special gold investment soars 2,300% ... 5,090% ... 9,850%
In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...
Weiss Ratings | Sponsored
Trump’s biggest move, misreported
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...
Porter & Company | Sponsored
Which Gold Miner Trades at 30% of NAV? The One Buffett Wants
Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...
Golden Portfolio | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored